伊维菌素:小型综述
本小型综述讨论阿维菌素类抗寄生虫药伊维菌素的作用机制、毒性与抗病毒证据。伊维菌素通过结合谷氨酸、GABA和甘氨酸等配体门控离子通道受体导致寄生虫麻痹死亡;因脊椎动物这些受体表达不同且伊维菌素为P-糖蛋白底物,哺乳动物毒性罕见,但P-糖蛋白基因多态性或合用P-糖蛋白抑制剂可能增加神经毒性。治疗性口服后其他毒性包括水肿、皮疹、头痛和眼部不适,多为轻度且持续时间短。伊维菌素在体外极高浓度下显示抗病毒作用,但药代动力学参数降低体内达到高浓度的可能性。作者结论:因不良事件(尤其神经毒性)顾虑及支持证据缺乏,目前不推荐将伊维菌素作为COVID-19的常规治疗或预防措施。
要点
- 伊维菌素为P-糖蛋白底物,P-糖蛋白基因多态性或合用P-糖蛋白抑制剂可能增加其神经毒性。
- 治疗性口服伊维菌素后的其他毒性包括水肿、皮疹、头痛和眼部不适,多为轻度且持续时间短。
- 伊维菌素仅在体外极高浓度下显示抗病毒作用,其药代动力学参数降低体内达到高浓度的可能性。
- 因神经毒性等不良事件顾虑及支持证据缺乏,目前不推荐伊维菌素用于COVID-19的常规治疗或预防。
研究设计与关键结果
- 伊维菌素作用机制为结合谷氨酸、GABA和甘氨酸等配体门控离子通道受体,导致寄生虫麻痹和死亡。
- 因脊椎动物离子通道受体表达不同,伊维菌素在哺乳动物中毒性罕见;伊维菌素为P-糖蛋白底物,限制其人体神经毒性。
- P-糖蛋白基因多态性或合用P-糖蛋白抑制剂可能增加伊维菌素的神经毒性。
- 治疗性口服伊维菌素后的其他毒性包括水肿、皮疹、头痛和眼部不适,多为轻度且持续时间短。
- 伊维菌素在体外极高浓度下显示抗病毒作用,但药代动力学参数降低体内达到高浓度的可能性。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,因不良事件(尤其神经毒性)顾虑及支持证据缺乏,目前不推荐将伊维菌素作为COVID-19的常规治疗或预防措施。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Introduction: Avermectins are common antiparasitic drugs, derived from Streptomyces bacteria that exhibit activity against arthropods and nematodes. Ivermectin, an avermectin derivative, is used as a treatment for parasitic infections in humans and domesticated animals.Discussion: Ivermectin's mechanism of action involves binding to ligand-gated ion channel receptors including glutamate, GABA, and glycine, resulting in parasitic paralysis and death. Due to varying expression of these ion channel receptors in vertebrate species, ivermectin toxicity is rarely reported in mammals. Ivermectin is also a substrate for P-glycoprotein, which limits its neurological toxicity in humans. Genetic polymorphisms in P-glycoprotein or coadministration of P-glycoprotein inhibitors may increase the neurotoxicity of ivermectin. Other toxic effects of ivermectin after therapeutic oral use include edema, rash, headache, and ocular complaints. Most of these effects are mild and short in duration. Ivermectin exhibits antiviral effects in-vitro at very high concentrations. This has led to suggestions of ivermectin as a potential treatment for SARS-CoV-2 (COVID-19) infection, although the drug's pharmacokinetic parameters reduce the likelihood that high concentrations of the drug can be achieved in-vivo.Conclusion: Due to concern for adverse events, specifically neurotoxicity, as well as a paucity of supporting evidence, the use of ivermectin as a routine treatment or preventive measure for COVID-19 infection is not recommended at this time.
参考来源
- Johnson-Arbor K. Ivermectin: a mini-review. Clin Toxicol (Phila). 2022. PMID: 35225114. doi:10.1080/15563650.2022.2043338
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。